Now I would like to hand the conference over to Mr. Aaron Gray, CEO. Please go ahead. Thank you, operator. Good morning, everyone, and thank you for joining Mayne Pharma's Fiscal Year 2026 full-year results presentation. I am Aaron Gray, Chief Executive Officer, and I am joined today by Griffin Buchanan, our Chief Financial Officer, who was appointed in August. Today I will begin with our Fiscal 2026 corporate highlights and global footprint. Griffin will then take you through the group financial performance before I return to walk through each of the three segments, women's health, dermatology, and DistributeRx, and international. We will then close with our future growth drivers and Fiscal Year 2027 focus and outlook. Then we will open the line for questions. Please take a moment to read the disclaimer regarding forward-looking statements and the use of non-IFRS measures. Today's comments should be read in conjunction with our audited financial statements and ASX disclosures. Excuse me. Turning to slide three and our Fiscal Year 2026 corporate highlights. Fiscal Year 2026 was a year of resilience and focus against a backdrop of considerable distraction and disruption. First, as part of our realignment of the women's health sales force, we refreshed our sales and marketing materials to better support the team in the field. We also introduced dedicated menopause and contraception field representation, which will allow us to drive deeper, more meaningful engagement with our high-value prescribers. In particular, we are increasing our focus on menopause given the strong structural tailwinds behind it, which includes favorable regulatory changes, rising awareness, and robust market growth. Second, we launched DistributeRx in March, a landmark step in our disintermediation strategy. DistributeRx is a healthcare solutions business that partners with manufacturers to streamline prescription distribution and expand patient access, and it has exceeded expectations thus far, necessitating expansion to a new facility, which will include capital equipment that enables continued growth at scale. The new facility is expected to enable a sevenfold increase in capacity over two phases. Finally, the Cosette transaction process and subsequent legal matters placed considerable demands on management focus and organizational bandwidth. We received AUD 14.4 million from Cosette in satisfaction of court-ordered legal costs and interest. The outcome of Cosette's appeal remains pending, and our damages claim against Cosette continues. We have also seen changes to the executive team and board. I was appointed CEO in February, having previously served as CFO, and Griffin joined as CFO in August. Professor Bruce Robinson was appointed Chair, and we welcomed two new non-executive directors following three retirements from the board, strengthening the experience around the table. I am confident we have the right team to deliver in FY 2027 and am excited by what the future holds for Mayne Pharma. This next slide sets out our global footprint. At 30 June 2026, the company employed a total of 470 people, 227 in the U.S. and 243 in Australia. The majority of our U.S. headcount is focused on sales, with our women's health sales force at 102 employees across 91 territories and our DistributeRx sales force at 28 employees across 23 territories. We operate in territories across the U.S. with dedicated company locations in Lexington, Kentucky, and in Raleigh, North Carolina. Our Australian employees are primarily supporting production at our facility in Salisbury, South Australia, developing and manufacturing products for sale into markets outside the U.S., including Canada, Europe, Asia, Australia, and New Zealand. Turning to our FY 2026 financial highlights on slide five. Group revenue was AUD 383.7 million, down 6% in Australian dollars on the prior year and significantly impacted by foreign exchange translation. Encouragingly, gross margin expanded to 64.7%, up 411 basis points, reflecting disciplined pricing, mix, and channel execution. Gross profit was essentially flat at AUD 248.1 million despite the lower revenue. Total direct segment contribution was AUD 107.1 million, down 2%. Underlying EBITDA was AUD 34.2 million, down 27% on the AUD 47 million delivered in fiscal year 2025. I do want to briefly address the increase of AUD 2.5 million to our underlying EBITDA between the announcement made on 31 July, when the company anticipated fiscal year 2026 underlying EBITDA of AUD 31.7 million to today's number of AUD 34.2 million. The 7.9% increase in underlying EBITDA announced today is driven by the company electing to treat the portion of share-based expense, which is attributable to retention as part of the continuing operations adjustments given the one-off nature of this expense. We closed the year with cash and marketable securities of AUD 80 million. I will now turn the call over to Griffin to run investors through our numbers at the group level and the segment level. Please go ahead, Griffin. Thank you, Aaron. I will cover our group performance before turning to our three segments. Turning to our continuing operations for FY 2026, reported revenue came in at AUD 383.7 million, down 6% on FY 2025's AUD 408.1 million. That decline was driven by three factors: appreciation of the Australian dollar against the U.S. dollar, a decline in dermatology from the loss of certain insurance coverage, competitive erosion on some brands, and a decline in the international as we transitioned our portfolio mix from lower- to higher-margin products and exited certain lines. Gross profit held essentially flat at AUD 248.1 million. Reported direct contribution was AUD 107.1 million, down 2% on the prior year, reflecting higher sales and marketing investment in women's health, continued investment behind NEXTSTELLIS PBS listing in Australia, and an increased OpEx dermatology tied to higher volumes through Adelaide Apothecary, partially offset by an 11% increase in dermatology's own contribution. Reported EBITDA was AUD 141.4 million, well above FY 2025's AUD 18.4 million. Though that comparison is affected by one-offs, litigation and restructuring charges, derivative fair value adjustment, and the largest impact coming from the lease of earn-out liabilities from a reduction in future revenue forecasts of certain licensed products. On an underlying basis, EBITDA was AUD 34.2 million, down 27% year-on-year. Operating cash flows from continuing operations was broadly stable at AUD 24.9 million, while adjusted operating cash flow was AUD 34.5 million, down 24%, reflecting the timing and scale of these one-offs. Slide eight bridges reported EBITDA to underlying EBITDA. Reported EBITDA was affected by significant scheme-related legal fees, including litigation, restructuring charges, and non-cash earn-out reassessment of the women's health portfolio. The earn-out reassessment is reflective of a reduction to future forecasted revenues, specifically for ANNOVERA. I have mentioned the reasons of the AUD 2.5 million increase in underlying EBITDA from the expectation we provided to the market on the 31st of July, reflecting the company's decision to treat the portion of share-based expense attributable to retention as part of the continuing operations adjustment given the one-off nature of this expense. In addition, an underlying basis, the year-on-year decline reflects the general business disruption caused by the Cosette transaction, our deliberate step-up in women's health sales and marketing together with the higher mandatory post-approval study cost. Unfavorable foreign exchange of approximately AUD 1.9 as the Australian dollar appreciated. Short-term incentives of approximately AUD 7.1 expected to be recognized in FY 2026 versus none in FY 2025. In the absence of prior period managed care true-up benefits of approximately AUD 5.6 million recognized in FY 2025. Underlying EBITDA is a non-IFRS measure and is unaudited. Slide nine walks you through the movement in cash and marketable securities from AUD 100.4 million at the 30th of June 2025 to AUD 80 million at the 30th of June 2026. The continuing business generated positive operating cash of approximately AUD 34.5 million, excluding the Cosette litigation and transactional cost of AUD 12.6 million. And we made payments of approximately AUD 12.5 million in royalties and a AUD 10.3 million earn-out payment for the TWYNEO and EPSOLAY acquisitions. The key message is the underlying business remains cash-generative, with the year's movement driven largely by discrete earn-out and litigation items. Turning to the segment performance. Slide 11 shows the FY 2026 revenue and contribution split across three segments. Women's health contributed revenue of AUD 174.3 million, dermatology AUD 138.7 million, and international AUD 70.7 million. On total direct contribution of AUD 100.7 million, women's health delivered AUD 57.9 million, dermatology AUD 44.5 million, and international AUD 4.6 million. Underlying women's health and dermatology as group's primary earning engines. Slide 12 summarizes the operating highlights across the three segments. In women's health, the FDA removed the black box warning on BIJUVA in February of 2026. We made a targeted investment in sales, marketing, and patient access. We completed a sales force optimization for the menopause and contraception specialist in key metro markets. We advanced the FDA-required post-marketing studies for ANNOVERA and IMVEXXY. In dermatology, we launched TWYNEO and EPSOLAY, successfully launched DistributeRx in March, secured a major two-phase expansion at Adelaide Apothecary, and broadened the DistributeRx platform. Signing the first third-party partner, we further manufacture agreement in negotiation. In international, we inaugurated AUD 18 million in the Salisbury facility upgraded, which was recognized in export and business awards. Importantly, secured the PBS approval for NEXTSTELLIS. In Australia, driving strong prescription growth, expanded KADIAN distribution in Canada, and improved delivered in full on time to 97.4%. Turning to the segment performance on slide 13. Women's Health is where the FX impact is most pronounced. Revenue was actually up 2% in U.S. dollar terms at $118.2 million but down 2% once translated to the Australian dollar at AUD 174.3 million. On an underlying consistent currency basis, the segment grew. That's reflected across the brand portfolio too. NEXTSTELLIS grew 6% in U.S. dollars to $45.2 million. BIJUVA grew 20% to 15 million U.S. dollars. Direct contribution came in at 57.9, down 7% on a reported basis. For dermatology, revenue was AUD 94.1 million, down 6% on the U.S. dollar basis, but once translated into U.S. dollars, that becomes $138.7 million, down 10%. Direct OpEx was up 4% to AUD 44.2 million. Gross profit rose 7% to AUD 88.7 million on a 63.9% margin. Direct contribution grew 11% to AUD 44.5 million. International delivered revenue of AUD 70.7 million, down 7%, with direct OpEx up 18% to AUD 16.7 million. Direct contribution down 38% to AUD 4.6 million. These figures are reported in Australian dollars without a material U.S. dollar cross-currency effect. I will now hand the call back to Aaron to walk through the particular segment highlights. Please go ahead, Aaron. Thanks, Griffin. Now going into some further detail on Women's Health. Slide 15 frames the menopause opportunity, which underpins BIJUVA and IMVEXXY. The category is being de-risked by regulation changes with the FDA's removal of the black box warning for certain hormone replacement therapies, including BIJUVA. There is a powerful demographic tailwind with around 75 million women in the United States now in peri or postmenopause and a further 1.3 million entering each year, a market that remains significantly underserved. Celebrity-led destigmatization is converting awareness into clinical demand. Payer coverage is expanding. Independent estimates see the menopause market growing from around $10 billion-$15 billion in 2026 to $15 billion-$25 billion by 2030, or an estimated 60% growth. We invested in a specialist menopause sales force in the second half, given the category's potential. BIJUVA delivered total prescription growth of 26% and net sales up 20% to $15 million. IMVEXXY grew prescription 6%, with net sales up 8% to $29.3 million. Slide 16 covers contraception and NEXTSTELLIS. Key drivers include expanding payer willingness to cover open, affordable contraceptive access under the Affordable Care Act, growing digital and direct-to-patient access through telehealth and online pharmacies, and improved payer coverage that drove a significant step-up in volumes in the fourth quarter. We added approximately 15 million additional covered lives in FY 2026. NEXTSTELLIS delivered demand cycles up 15% and net sales up 6% to $45.2 million. ANNOVERA saw prescriptions up 2%, though net sales were down 13% to $25.7 million, reflecting persistent product returns, which we are actively working to address. Turning now to dermatology and DistributeRx on slide 17. Slide 18 shows how a shift in our dermatology product mix is driving margin and contribution growth. Branded products increased as a share of the portfolio from around 54% in fiscal year 2025 to 58% in fiscal year 2026. That shift, combined with continued channel optimization, drove gross margin and contribution growth even against a lower revenue base. Slide 19 sets out our dermatology portfolio, a mix of branded and generic products. Six branded products and 25 generic and authorized generic products for 31 total Mayne Pharma dermatology products, with long-dated patent protection extending in some cases to 2041. I should note that a generic RHOFADE launched in July 2026 as expected. Slide 20 explains our disintermediation strategy. Removing intermediaries between Mayne Pharma as manufacturer and between the patient. The U.S. pharmacy distribution system creates real friction. Handoffs, stage gates, opaque financial incentives, and obstructions that increase cost to patients and manufacturers through rebates and fees increase unfilled prescriptions from barriers and outright abandonment and create significant additional effort to patients and HCPs to attempt to get the prescribed medication into the hands of the patient. DistributeRx, with Adelaide Apothecary as our licensed cash-pay pharmacy arm, addresses that friction. Mayne has been focused on these problems for five-plus years, and as a result, fiscal year 2026 saw approximately 60% of our U.S. women's health and dermatology volumes move through those non-traditional channels. Slide 21. DistributeRx is a wholly owned subsidiary of Mayne Pharma, focused on partnership with manufacturers, providers, and pharmacies to improve patient access and offer predictable prices. We compete in the ePharmacy market space. This market is expected to reach around $252 billion by 2030. The launch of DistributeRx materially exceeded expectations, delivering strong prescription growth ahead of forecast and the prior corresponding period, with around 5,000 new prescribers added since launch. In May, we announced a major expansion of Adelaide Apothecary in Lexington, Kentucky, lifting capacity to up to 2.5 million prescriptions per annum across two phases, with around $4 million invested for capital equipment and automation. Slide 22 shows the total DistributeRx portfolio, including the Mayne Pharma and non-Mayne products. At present, the channel carries the previously mentioned 31 Mayne Pharma dermatology products, alongside a further 208 third-party products, with a pipeline of additional products across several new manufacturers, including our first third-party partnership with Resilia Pharmaceuticals, announced 1st of June 2026. Turning now to our final segment, international. NEXTSTELLIS was added to the PBS on the 1st of October 2025. With around 1.7 million Australian women using contraception each year and following our investment in sales and marketing post-listing, we have generated strong prescription growth, with Australian demand cycles rising materially through the second half and reaching record. Slide 25 sets out our future growth drivers. In women's health, our strong intellectual property and current market share provides ample headroom to continue to grow all products. We have a significant market opportunity in the hormone replacement therapy space, with the promotion, sales execution, and access all in the right position at the right time to pursue this opportunity. In dermatology, the Mayne products can address as many as one in three derm conditions, and there is an acute and growing need for improved patient access, price transparency, and process efficiency. The DistributeRx solution has been purpose-built, tested, and launched to address these needs. We do see opportunities to continue to expand our asset portfolio with a focus on profitability and capital efficiency and, as mentioned, have a number of promising manufacturing partnerships in work. In international, NEXTSTELLIS growth has accelerated following the PBS tailwind, and the Salisbury capacity upgrade, together with significant business development efforts, will add partnerships to grow exports and add products. Slide 26 summarizes our fiscal year 2027 focus. In women's health, we will leverage the current commercial structure to grow where the opportunities are greatest. Improved coverage on NEXTSTELLIS, removal of the black box warning on BIJUVA, and general increase in awareness on hormone replacement therapies to treat menopause create significant opportunity. We will further optimize how our products move through distribution channels to improve patent, patient, and manufacturer outcomes. In dermatology, we will grow the portfolio and optimize supply and pricing in the face of some anticipated loss of insurance coverage on TWYNEO and generic entry against RHOFADE. DistributeRx will be focused on prescription growth with addition of territories, products, and partnerships driving growth in new and repeat writers. In international, we will build on NEXTSTELLIS growth and leverage the Salisbury investment for export and contract manufacturing growth. At a corporate level, we will continue to evaluate capital-efficient, synergistic acquisitions alongside disciplined capital management. In closing, fiscal year 2026 was a year in which we strengthened the foundations of the business, and we enter fiscal year 2027 with clear commercial momentum and a disciplined plan to convert it into durable, profitable growth. I would like to thank all of the Mayne Pharma employees who all contributed to make that happen. That concludes our formal presentation. Griffin and I would now be happy to take your questions. Our investor relations contact details are on screen. Thank you. If you would like to ask a question via the phone, you will need to press the star key followed by the number one on your telephone keypad. If you would like to ask a question via the webcast, please type your question into the Ask a Question box and click Submit. I would first like to hand over to Mr. Tom Duthy to address any pre-submitted questions. Thank you very much, Darcy. We have had a couple of questions relating to the DistributeRx manufacturing pipeline or manufacturer pipeline. Aaron, this is a consolidated question. One DistributeRx manufacturer, Resilia Pharmaceuticals, is signed, and seven more are in negotiation covering 13 pipeline products. What revenue uplift should the market expect as those progressively convert, and on what timeline do we anticipate these to be converted? Thank you. Thanks, Tom, and thanks for the question. The expansion for these arrangements is driven by manufacturers seeing what Mayne Pharma sees. Namely, that DistributeRx has a value-added channel for their products. As mentioned, we have seven additional manufacturers in negotiation covering 13 different products. We would expect to convert a significant percentage of those manufacturers in the near term. We do not specifically provide revenue guidance for DistributeRx but do expect to be able to provide the market with some numbers at the first half of fiscal year 2027. We do anticipate extending beyond dermatology as well. Some of those products that we would add may expand beyond the dermatology therapeutic area. Thank you, Aaron. The next question relates to menopause. Menopause is clearly central to your growth story, BIJUVA and IMVEXXY, and the FDA black box warning removal. With Mayne Pharma as currently indicated to the market, holding a very low single-digit share of these markets. The question is, why are you so confident menopause is a growth driver for this business, and what needs to be true for Mayne to capture a disproportionate share of that expansion? Thanks for that question. Menopause has been an area that was, especially in the U.S., severely impacted by a study that was performed in 2002. In the year 2000, as many as 27% of women in the United States used hormone replacement therapy for menopause symptoms. Following the WHI study that I mentioned in 2002, that usage declined to around 4%-6% of women. The use declined from 27% to something around 5%. Consumer behavior, knowledge of healthcare providers, and regulators signaling an increased acceptance with black box warning removal have all spurred significant growth, with this market expected to grow as much as 60% by 2030. A reasonable proxy is Europe, where today approximately 16% of women use hormone replacement therapy for menopause symptoms. The products that we have are best-in-class products. They have an accretive cash profile versus some of our other products, and they've been at the center of some of the investments that we've made to increase digital and in-person promotion of menopause products. The growth that we've seen to date actually predates those investments. We've made targeted investments. We've made those investments with very grounded assessments of what those investments will be worth, and we are already seeing the positive results of those investments. Thank you. We have a question relating to the gross margin in women's health. There was a decline in FY 2026. The question is, can you comment on the direction of the women's health gross margin into FY 2027? We would generally expect the gross margins to improve between fiscal year 2026 and fiscal year 2027. We continue to see growth in the women's health products. Fiscal year 2025 was buoyed by a managed care adjustment of about $5.6 million, which was non-recurring in fiscal year 2026. It was an inflation on fiscal year 2025 that we didn't see again in fiscal 2026. That was a function of some of the conservativism that I as CFO held in the gross-to-net estimation as we overhauled all of our processes, all of our data, et cetera, over a multi-year period. We continue to refine our approach there, but our approach has proven to be quite accurate. Hence, we didn't need to hold the same level of conservativism. We also saw that fiscal year 2026 was heavily weighed down with over $11 million USD of product returns on ANNOVERA, and that is $11 million USD negative revenue, or debit to revenue, reduction of revenue, with a straight hit to profit. We are working on changing the way that product is handled and treating that product more as a specialty product than as a standard pharmacy product that runs through a more traditional channel. The size of the opportunity there as well is $11 million. In addition to that, the increase in NEXTSTELLIS coverage that I mentioned with the expansion of covered lives gives us a higher mix of covered transactions compared to cash transactions. We would expect some volume of cash transactions to move to covered. Overall, that mix effect would be expected to be accretive to the fiscal year 2026 margin profile. Thank you, Aaron. Just while we are on women's health and the women's health product, this relates to the international business. NEXTSTELLIS Australian demand is up strongly since PBS listing. Is this a function of the PBS cost effect for patients or the sales and marketing push? That is a function of both. A three-month supply of NEXTSTELLIS now costs a patient in Australia AUD 25, which is one factor, putting us on equal footing with other oral contraceptives. Another factor is that the unique profile of the product, which has been central to being able to drive increased sales. We have promoted the product. The product is a differentiated superior product, and it is now on equal footing with other oral contraceptives that are on the PBS. We have a solid runway there, and we expect to see continued growth for this product in Australia. Thank you, Aaron. This question relates to guidance. Is there any guidance for one-off costs moving forward, and can you provide any updates on the legal scheme costs moving forward? We don't provide guidance on one-off costs. By their nature, they're relatively difficult to guide upon or predict. We've significantly reduced the one-off costs to having exited the generics business and running down a large portion of the surprises that come there, as a function of either Inflation Reduction Act topics, product returns, legacy matters that were part of the core thesis for us to exit the generics business. We've significantly run that down. I would expect that to be lower year-on-year than what we've experienced. With respect to other one-off costs, scheme costs, there are no further costs for the scheme with Cosette. We only would have litigation costs, which we don't provide guidance information to the market, but we would not expect the litigation cost to be outsized relative to other matters that are similar. The litigation forward-looking runs on a more normal timeframe and a more normal scale compared to what we worked through in the determination of the scheme. Thank you. This just relates to the growth opportunity for ePharmacy and DistributeRx generally. You've mentioned on the call today that the ePharmacy market is forecast to reach $252 billion U.S. by 2030. The question is, what structural shift in U.S. pharmacy distribution makes now the right time for DistributeRx, and how is Mayne positioned to grow this business unit strongly over time? The U.S. healthcare system and consumer awareness are reaching a point being a participant in the U.S. healthcare system and a consumer, where patients see diminishing and maybe little or no value in having insurance. In many cases, paying cash for a product is less costly to the patient than using their insurance, and that doesn't even include the cost of having the insurance. In many cases, the sum of the fees paid across the standard value flow for a pharmaceutical product exceed the net realized price of the product by multiples of two to four times. Product availability can be a challenge. We've seen vertical integration and financial incentives between large payers, pharmacy benefit managers, and pharmacies, which have the effect to limit patient and provider choice. This is really something that Mayne's been battling for the past five-plus years. Mayne is an early mover in this space, and our solutions have been designed and tested pretty significantly. Our solution is embedded in workflow in the office, which makes using our solution much more convenient for the provider and the patient. It works. Our solution is one of the only solutions, maybe the only solution, that works with insured and cash patients and provides them with transparency to make the choice themselves. This solution also only provides pharmacy options that actually dispense the drug the HCP has prescribed. It is not a script that gets sent to your neighborhood pharmacy, which, if it happens to be one of the vertically integrated pharmacies, who shall remain nameless on the call, could result in switching due to some of the aforementioned financial incentives or some of the barriers that are put in place. Since we have launched this in March, we have significantly scaled the business and are actually operating at or above full capacity at Adelaide Apothecary. Shout out to that team, and thanks to Jill and the full team. Hence the relocation and investment in a new facility. The growth we have realized to date is driven by dermatology products, but the solution also works quite well for any non-acute prescription that has poor or low insurance coverage. That creates the potential to expand to other therapeutic areas, other products, and the need is real, because of all these structural matters, for products well beyond dermatology. Great. Thank you, Aaron. The next question relates to some of the media speculation regarding Mayne Pharma over the preceding weeks. How widespread is the shareholder disquiet that has been expressed publicly, and what is Mayne's response? We do not comment on market speculation. We will, of course, comply with our continuous disclosure obligations if a matter requiring disclosure arises. I would just say that we do not comment on market speculation. Thank you, Aaron. I would like to turn the call back over to Darcy for a phone question. Over to you, Darcy. Thank you. Once again, if you would like to ask a question, please press star one on your telephone and wait for your name to be announced. Your first question from the phone comes from Andrew Goodsall from MST Marquee. Please go ahead. Oh, good morning. Thanks for taking my question. Just trying to understand direction of travel for the gross profit margins. Just looking at first half, second half 2026 comparisons and starting with Women's Health, it doesn't look like there's been a big turnaround, but I guess you might have better visibility on direction of travel with those margins, just particularly with maybe the last quarter. Yeah. One of the things to remember, Andrew, and thanks for the question. One of the things to remember is that our second half experiences significant seasonality following the co-pay resets in the U.S. healthcare system that happened at the beginning of January. We typically see a significant reduction in covered scripts and a significant increase in cash scripts during the first half. We also continued to suffer the returns topic that I mentioned on ANNOVERA across the second half, and that hit us to a discrepant portion. The seasonality will continue. That is just an artifact of the system that we are in to the extent that we continue to derive a significant portion of our margins from covered business. However, we are actively working to address the ANNOVERA returns. It is not an overnight thing that we can do but, as I mentioned, that was an AUD 11 million impact in fiscal year 2026. And I guess just in terms of direction, with adding to the portfolio and so on, is your expectation or ambition to get those margins up? Yeah. Generally, we would expect that those margins would increase. As we increase the mix of covered scripts that the weighted average skews towards more coverage on NEXTSTELLIS with the additional covered lives that I have mentioned. We will have fewer cash scripts at a lower profit margin. We have implemented a number of things to try and improve our overall margins, continuing to refine co-pay monitoring and different pharmacy partnerships and how we manage those partnerships. Obviously we will address the ANNOVERA returns as well. We do not see barriers to be able to continue to drive some of those margins. We also continue to have the option of price increases. There can be some cost inflation, but, generally speaking, we would expect the margins to hold and slightly accrete. Okay. I know it is early days, but just the launch of TWYNEO and EPSOLAY—just any sort of reaction to how they are tracking? Andrew, you are breaking up pretty bad. I think there is an interference on the line. Yeah, I could hear it. Just EPSOLAY and TWYNEO, just how they are tracking. TWYNEO and EPSOLAY have been tracking basically on plan for us. They have significantly lifted the overall gross margin of the dermatology portfolio, which is what you can see with the gross margin development. That development year-on-year, the increase in the gross margin is a function of having added TWYNEO and EPSOLAY to the portfolio. So they are tracking reasonably well. They are solid products with really long patent lives and so we expect to be able to continue to derive margin from them. I did note in the presentation that we lost some amount of coverage on TWYNEO, so we would expect that there is some amount of price impact throughout fiscal year 2027. But the product continues to be a really good product for us. We are very happy with it. Thank you. As there are no further phone questions, I will now hand back to Mr. Aaron Gray for any closing remarks. Thank you very much, operator. Appreciate it. Thanks, everybody, for joining. Again, fiscal year 2026 was a tough year for the company because that transaction ended in December. It has been a relatively short time that we have been turning things around, getting people back engaged. I would just like to repeat what I said earlier, which was thanking all of the employees of the company for sticking with us and for helping to bring us to this stage. We are well-positioned for fiscal year 2027 with all of the work that has been done. That does conclude our conference for today. Thank you for participating. You may now disconnect.